Published in Int J Mol Med on January 01, 2001
Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci U S A (2005) 2.70
Tetraspanins as regulators of the tumour microenvironment: implications for metastasis and therapeutic strategies. Br J Pharmacol (2014) 1.01
Identification and characterization of renal cell carcinoma gene markers. Cancer Inform (2007) 0.92
The tetraspanin CD81 protein increases melanoma cell motility by up-regulating metalloproteinase MT1-MMP expression through the pro-oncogenic Akt-dependent Sp1 activation signaling pathways. J Biol Chem (2014) 0.85
Tetraspanin CO-029 inhibits colorectal cancer cell movement by deregulating cell-matrix and cell-cell adhesions. PLoS One (2012) 0.81
The fibrotic microenvironment as a heterogeneity facet of hepatocellular carcinoma. Fibrogenesis Tissue Repair (2013) 0.76
Tspan2: a tetraspanin protein involved in oligodendrogenesis and cancer metastasis. Biochem Soc Trans (2017) 0.75
Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A (1990) 6.96
Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology (2001) 2.62
Interferon therapy for patients more than 60 years of age with chronic hepatitis C. J Gastroenterol Hepatol (1995) 1.48
Low stimulatory capacity of lymphoid dendritic cells expressing hepatitis C virus genes. Biochem Biophys Res Commun (1998) 1.31
Macrophage migration inhibitory factor in the sera and at the colonic mucosa in patients with ulcerative colitis: clinical implications and pathogenic significance. Eur J Clin Invest (2001) 1.28
Mechanism of action of vaccine therapy in murine hepatitis B virus carriers: vaccine-induced activation of antigen presenting dendritic cells. J Hepatol (1999) 1.27
Immunosuppressive functions of hepatic myeloid-derived suppressor cells of normal mice and in a murine model of chronic hepatitis B virus. Clin Exp Immunol (2011) 1.26
Microwave coagulation therapy for hepatocellular carcinoma. Gastroenterology (1996) 1.21
Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J Hepatol (1999) 1.16
Noninvasive diagnosis of the degree of hepatic fibrosis using ultrasonography in patients with chronic liver disease due to hepatitis C virus. Eur J Clin Invest (2001) 1.15
Low responsiveness of hepatitis B virus-transgenic mice in antibody response to T-cell-dependent antigen: defect in antigen-presenting activity of dendritic cells. Immunology (1993) 1.13
Upregulation of MHC class II antigen on dendritic cells from hepatitis B virus transgenic mice by interferon-gamma: abrogation of immune response defect to a T-cell-dependent antigen. Immunology (1996) 1.07
Hepatitis B virus (HBV)-transgenic mice as an investigative tool to study immunopathology during HBV infection. Int J Exp Pathol (1998) 1.07
Decreased interferon-alpha production and impaired T helper 1 polarization by dendritic cells from patients with chronic hepatitis C. Clin Exp Immunol (2004) 1.06
Macrophage migration inhibitory factor activates antigen-presenting dendritic cells and induces inflammatory cytokines in ulcerative colitis. Clin Exp Immunol (2002) 1.05
Transfer of dendritic cells (DC) ex vivo stimulated with interferon-gamma (IFN-gamma) down-modulates autoimmune diabetes in non-obese diabetic (NOD) mice. Clin Exp Immunol (1999) 1.03
Production of antibody to hepatitis B surface antigen (anti-HBs) by murine hepatitis B virus carriers: neonatal tolerance versus antigen presentation by dendritic cells. Immunology (1997) 1.01
Macrophage migration inhibitory factor in hepatocellular carcinoma and liver cirrhosis; relevance to pathogenesis. Cancer Lett (2001) 1.01
Mutational analysis of ATP7B and genotype-phenotype correlation in Japanese with Wilson's disease. Hum Mutat (2000) 0.99
Increased serum levels of macrophage migration inhibitory factor in alcoholic liver diseases and their expression in liver tissues. Clin Biochem (2001) 0.98
Characterization of antigen-presenting dendritic cells in the peripheral blood and colonic mucosa of patients with ulcerative colitis. Eur J Gastroenterol Hepatol (2001) 0.97
Prognostic importance of antigen-presenting dendritic cells during vaccine therapy in a murine hepatitis B virus carrier. Immunology (1999) 0.97
Increased serum soluble interleukin 2 receptor levels in patients with viral liver diseases. Hepatogastroenterology (1988) 0.96
Hepatitis C virus clearance is prominent in women in an endemic area. J Gastroenterol Hepatol (2000) 0.96
Mechanism and therapeutic potential of DNA-based immunization against the envelope proteins of hepatitis B virus in normal and transgenic mice. Immunology (2001) 0.95
Amyloidosis localized in the sigmoid colon. J Gastroenterol (1996) 0.95
Absence of CD83-positive mature and activated dendritic cells at cancer nodules from patients with hepatocellular carcinoma: relevance to hepatocarcinogenesis. Cancer Lett (2000) 0.95
Present status of autoimmune hepatitis in Japan. Gastroenterol Jpn (1993) 0.95
Impaired functional capacities of liver dendritic cells from murine hepatitis B virus (HBV) carriers: relevance to low HBV-specific immune responses. Clin Exp Immunol (2005) 0.93
Existence of TT virus DNA in extracellular body fluids from normal healthy Japanese subjects. Intervirology (2000) 0.93
Isolation and functional analysis of circulating dendritic cells from hepatitis C virus (HCV) RNA-positive and HCV RNA-negative patients with chronic hepatitis C: role of antiviral therapy. Clin Exp Immunol (2004) 0.92
Dendritic cells and chronic hepatitis virus carriers. Intervirology (2001) 0.92
Placebo-controlled trial of vaccination with hepatitis B virus surface antigen in hepatitis B virus transgenic mice. J Hepatol (1997) 0.91
Prediction of prognosis of primary biliary cirrhosis in Japan. Liver (1995) 0.89
Increased nitric oxide (NO) production by antigen-presenting dendritic cells is responsible for low allogeneic mixed leucocyte reaction (MLR) in primary biliary cirrhosis (PBC). Clin Exp Immunol (1998) 0.89
Abnormal gastric motility in liver cirrhosis: roles of secretin. Dig Dis Sci (1998) 0.89
A novel and effective approach of developing aggressive experimental autoimmune gastritis in neonatal thymectomized BALB/c mouse by polyinosinic:polycytidylic acid. Clin Exp Immunol (2004) 0.88
Intrahepatic lymphocyte subpopulations and HLA class I antigen expression by hepatocytes in chronic hepatitis C. Hepatogastroenterology (1992) 0.88
Localization and characterization of antigen-presenting dendritic cells in the gastric mucosa of murine and human autoimmune gastritis. Eur J Clin Invest (2000) 0.86
X region deletion variants of hepatitis B virus in surface antigen-negative infections and non-A, non-B hepatitis. J Infect Dis (1995) 0.86
Peripheral blood T-cell responses to pyruvate dehydrogenase complex in primary biliary cirrhosis: role of antigen-presenting dendritic cells. Eur J Clin Invest (2001) 0.85
Mechanisms of alcoholic liver disease: cytokines. Alcohol Clin Exp Res (2001) 0.85
Potent synergistic effect of sho-saiko-to, a herbal medicine, during vaccine therapy in a murine model of hepatitis B virus carrier. Eur J Clin Invest (1999) 0.85
Increased levels of serum interleukin-12 in Graves' disease. Eur J Endocrinol (1999) 0.84
Cronkhite-Canada syndrome. A case report and analytical review of 23 other cases reported in Japan. Gastroenterol Jpn (1979) 0.84
Immunohistochemical localization of antigen presenting cells in liver from patients with primary biliary cirrhosis; highly restricted distribution of CD83-positive activated dendritic cells. Pathol Res Pract (1999) 0.84
Impaired dendritic cell functions because of depletion of natural killer cells disrupt antigen-specific immune responses in mice: restoration of adaptive immunity in natural killer-depleted mice by antigen-pulsed dendritic cell. Clin Exp Immunol (2008) 0.84
Morphometric analysis of lymphatic and blood vessels in human chronic viral liver diseases. Am J Pathol (1998) 0.84
Antigen-presenting cells at the liver tissue in patients with chronic viral liver diseases: CD83-positive mature dendritic cells at the vicinity of focal and confluent necrosis. Hepatol Res (2001) 0.84
Hepatitis B X open reading frame deletion mutants isolated from atypical hepatitis B virus infections. J Hepatol (1991) 0.84
Safety and immunogenicity of hepatitis B surface antigen-pulsed dendritic cells in patients with chronic hepatitis B. J Viral Hepat (2011) 0.84
Effect of recombinant interleukin 2 on hepatitis B e antigen positive chronic hepatitis. Gut (1987) 0.83
Primary carcinoid tumor of the liver: report of two cases with an emphasis on US findings. Abdom Imaging (2002) 0.83
In situ characterization of dendritic cells occurring in the islets of nonobese diabetic mice during the development of insulitis. Pancreas (2000) 0.83
Serum levels of soluble CD4 and CD8 in patients with chronic viral hepatitis. Hepatogastroenterology (1994) 0.83
Serum IL-8 levels and localization of IL-8 in liver from patients with chronic viral hepatitis. Hepatogastroenterology (1999) 0.83
[The efficacy of lidocaine in the status epilepticus (author's transl)]. No To Shinkei (1980) 0.82
Increased serum levels of macrophage inflammatory protein-3alpha in chronic viral hepatitis: prognostic importance of macrophage inflammatory protein-3alpha during interferon therapy in chronic hepatitis C. J Viral Hepat (2002) 0.82
Anti-HCV immunoglobulin M antibody in patients with acute and fulminant hepatitis C. Gastroenterol Jpn (1993) 0.81
Precore and X region mutants in hepatitis B virus infections among renal dialysis patients. J Viral Hepat (1995) 0.80
Assay of serum interleukin 8 levels in patients with alcoholic hepatitis. Alcohol Alcohol Suppl (1993) 0.80
Unique features of dendritic cells in IFN-gamma transgenic mice: relevance to cancer development and therapeutic implications. Biochem Biophys Res Commun (1999) 0.80
The effectiveness of interferon therapy on occurrence of hepatocellular carcinoma in chronic hepatitis C. Oncol Rep (1998) 0.79
[An epidemiological study of hepatitis C virus infection in a local district in Japan]. Rinsho Byori (1991) 0.79
Hepatitis C virus plus- and minus- strand RNA in hepatocellular carcinoma and adjoining nontumorous liver. J Med Virol (1993) 0.79
p53 mutation without allelic loss and absence of mdm-2 amplification in a transplantable hamster pancreatic ductal adenocarcinoma and derived cell lines but not primary ductal adenocarcinomas in hamsters. Mol Carcinog (1995) 0.79
Induction of CINC (interleukin-8) production in rat liver by non-parenchymal cells. J Gastroenterol Hepatol (1998) 0.79
Chemoembolization and percutaneous ethanol injection for intrahepatic recurrence of hepatocellular carcinoma after hepatic resection. Hepatogastroenterology (1997) 0.79
Proatlantal intersegmental artery with absence of bilateral vertebral arteries. Case report. J Neurosurg (1981) 0.78
[A case of hemophagocytic syndrome with severe liver injury manifestating adult Still's disease]. Nihon Rinsho Meneki Gakkai Kaishi (1997) 0.78
Influence of RNA titre and amino acid changes in the NS5A region of GB virus c/hepatitis G virus on the effectiveness of interferon therapy. J Gastroenterol Hepatol (2000) 0.78
Immunologic effects on peripheral lymphoid cells from patients with chronic hepatitis type B during administration of recombinant interleukin 2. Clin Exp Immunol (1988) 0.78